AFIRMA.COM: Keyword Density Checker

Total words: 1739 | 2-word phrases: 457 | 3-word phrases: 495 | 4-word phrases: 507

PAGE INFO

Title	Try to keep the title under 60 characters (38 characters) Afirma® Thyroid Molecular Diagnostics
Description	Try to keep the meta description between 50 - 160 characters (138 characters) The Afirma® Thyroid Molecular Diagnostics Test is a comprehensive solution that helps inform personalized thyroid care for your patients.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	impact of afirma	11	2.22%
2	afirma gsc on	11	2.22%
3	the impact of	11	2.22%
4	gsc on 100	11	2.22%
5	on 100 patients	10	2.02%
6	of afirma gsc	10	2.02%
7	100 patients with	10	2.02%
8	patients with biiiiv	10	2.02%
9	with biiiiv nodules	9	1.82%
10	nodules the impact	8	1.62%
11	biiiiv nodules the	7	1.41%
12	manage patient reports	4	0.81%
13	with the veracyte	4	0.81%
14	easily manage patient	4	0.81%
15	patient reports with	3	0.61%
16	reports with the	3	0.61%
17	the veracyte portal	3	0.61%
18	rule out surgery	3	0.61%
19	for your patient	3	0.61%
20	to provide a	3	0.61%
21	a combination of	2	0.40%
22	world performance metaanalysis	2	0.40%
23	benign call rate	2	0.40%
24	than validation16 67	2	0.40%
25	ppv significantly better	2	0.40%
26	65 ppv significantly	2	0.40%
27	npv 65 ppv	2	0.40%
28	99 npv 65	2	0.40%
29	sensitivity 99 npv	2	0.40%
30	clinical settings16 97	2	0.40%

#	Keyword	Frequency	Density
1	of afirma gsc on	10	1.97%
2	gsc on 100 patients	10	1.97%
3	the impact of afirma	10	1.97%
4	impact of afirma gsc	10	1.97%
5	afirma gsc on 100	10	1.97%
6	100 patients with biiiiv	9	1.78%
7	on 100 patients with	9	1.78%
8	nodules the impact of	8	1.58%
9	patients with biiiiv nodules	8	1.58%
10	with biiiiv nodules the	6	1.18%
11	biiiiv nodules the impact	6	1.18%
12	easily manage patient reports	4	0.79%
13	reports with the veracyte	3	0.59%
14	patient reports with the	3	0.59%
15	manage patient reports with	3	0.59%
16	hürthleoncocytic cells35 3 in	2	0.39%
17	site veracyte site veracyte	2	0.39%
18	cell lesions as benign67911	2	0.39%
19	lesions as benign67911 89	2	0.39%
20	benign67911 the impact of	2	0.39%
21	cells35 3 in 4	2	0.39%
22	nodules resulted in afirma	2	0.39%
23	resulted in afirma gsc	2	0.39%
24	transcripts and chromosomal level	2	0.39%
25	and chromosomal level loss	2	0.39%
26	patient site veracyte site	2	0.39%
27	leverages a combination of	2	0.39%
28	call rate clinically validated	2	0.39%
29	performance metaanalysis of 13	2	0.39%
30	assessing afirma’s performance in	2	0.39%
31	afirma’s performance in diverse	2	0.39%
32	sensitivity 99 npv 65	2	0.39%
33	99 npv 65 ppv	2	0.39%
34	npv 65 ppv significantly	2	0.39%
35	65 ppv significantly better	2	0.39%
36	benign call rate clinically	2	0.39%
37	rate clinically validated through	2	0.39%
38	gsc leverages a combination	2	0.39%
39	clinically validated through a	2	0.39%
40	multicenter study published in	2	0.39%

#	URL	Whois	Check
1	https://www.veracyte.com/	Whois	veracyte.com
2	https://portal.veracyte.com/	Whois	veracyte.com
3	https://www.veracyte.com/news-events/events?cat=%5B%5D&prod=%5B%22AFIRMA%C2%AE%22%5D&loc=%5B%5D	Whois	veracyte.com
4	https://www.veracyte.com/	Whois	veracyte.com
5	https://portal.veracyte.com/	Whois	veracyte.com
6	https://www.veracyte.com/news-events/events?cat=%5B%5D&prod=%5B%22AFIRMA%C2%AE%22%5D&loc=%5B%5D	Whois	veracyte.com
7	https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/datasheet-truseq-rna-access.pdf	Whois	illumina.com